Drugs / Hyperimmune plasma
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04366245 | Apr → Dec 2020 | COVID-19 | Andalusian Network for Design and Translation of Advanced Therapies | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hyperimmune plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04366245 ↗ |
| Modality | Protein / enzyme biologic | “hyperimmune plasma obtained from convalescent antibodies of COVID-19 infection” NCT04366245 ↗ |